Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19

NACompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
COVID-19
Interventions
DEVICE

Viruxal Oral and Nasal Spray

Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.

OTHER

Placebo

The placebo will be a similar spray containing saline only.

Trial Locations (1)

101

National Hospital of Iceland (Landspítali), Reykjavik

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kerecis Ltd.

INDUSTRY

NCT04357990 - Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19 | Biotech Hunter | Biotech Hunter